전 세계적으로 심혈관질환의 증가로 최소침습적 치료에 대한 수요가 증가하고 있습니다. 특히 선진국의 고령화와 심장 및 혈관 질환 발생률이 높아짐에 따라 고도의 의료 개입이 필요하며, 2024년 시장 규모는 240억 8,000만 달러를 돌파하고 2031년에는 436억 4,000만 달러에 달할 것으로 예상됩니다.
또한, 약물 용출성 스텐트, 생체흡수성 혈관 비계, 카테터 기반 신기술 개발 등 현재 진행 중인 기술 발전으로 인해 이러한 시술의 효과와 안전성이 향상되고 있습니다. 의료비 증가와 심혈관질환의 조기 발견 및 치료의 이점에 대한 인식이 높아지면서 2024년부터 2031년까지 약 8.51%의 CAGR로 성장할 것으로 예상됩니다.
심혈관 중재시술 및 말초혈관 기기 시장 정의/개요
심혈관 중재시술 및 말초혈관 기기는 심장 혈관과 말초동맥에 영향을 미치는 질환을 진단하고 치료하는 데 사용되는 특수 의료기기 및 임플란트입니다. 스텐트, 카테터, 풍선, 가이드와이어 등은 관상동맥 질환, 말초동맥 질환 및 기타 혈관 질환을 치료하기 위한 최소침습적 시술에 사용되는 기구 중 하나입니다. 이러한 기구의 사용은 개복 수술 없이 혈류를 회복하고 심장마비 위험을 낮추며 환자의 예후를 개선하는 데 필수적입니다. 기술의 발전, 세계 인구의 고령화, 심혈관질환의 유병률 증가로 인해 이 시장의 미래는 유망합니다. 생체흡수성 스텐트 및 약물 용출 기술 개발과 같은 지속적인 기술 혁신과 신흥 시장의 의료 인프라 확장은 이러한 기기의 세계 성장과 보급을 촉진할 것으로 예상됩니다.
최소침습적 시술에 대한 수요가 증가함에 따라 심혈관 중재시술 및 말초혈관 기기 시장이 성장할 것으로 예상됩니다. 스텐트, 풍선, 카테터와 같은 최소침습적 시술은 기존 개복 수술에 비해 회복 시간 단축, 입원 기간 단축, 합병증 발생률 감소 등 여러 가지 이점을 제공합니다. 심혈관계 질환이 여전히 전 세계 사망원인 1위로 꼽히는 가운데, 헬스케어 업계는 환자의 예후를 개선하기 위해 보다 침습적이지 않은 첨단 시술에 대한 의존도를 높이고 있습니다. 이러한 시술은 만성 심장 질환이 많은 선진국의 노인들에게 특히 인기가 높습니다.
2024년 6월, 메드트로닉은 말초동맥 질환 치료에 사용되는 새로운 최소침습 풍선 카테터에 대한 FDA 승인을 받았습니다. 이 기기는 주변 조직에 미치는 영향을 최소화하면서 정확한 치료를 가능하게 하며, 혈관 치료에서 비침습적 솔루션의 확대 추세를 강조하고 있습니다. 2024년 5월, 보스턴 사이언티픽은 최신 약물 용출 스텐트도 발표했습니다. 이 스텐트는 관상동맥 재협착을 감소시켜 개심술에 대한 보다 안전하고 효과적인 치료 대안을 제공하는 것을 목표로 합니다.
2024년 3월, 유럽의약품청(EMA)은 생명을 구하는 기술에 대한 신속한 접근이라는 중요한 요구를 인식하고 최소침습적 심혈관계 기기의 승인 절차를 가속화하기 위한 새로운 규제 이니셔티브를 발표하였습니다. 이러한 정책은 더 많은 기업들이 중재적 심장학 분야에서 혁신을 이루도록 장려하기 위한 것입니다. 전반적으로, 전 세계 의료 시스템이 환자의 안전과 비용 효율성을 우선시함에 따라 최소침습적 시술에 대한 수요가 심혈관 중재시술 및 말초혈관 기기 시장의 성장을 촉진할 것으로 예상됩니다.
첨단 의료기기의 높은 비용으로 인해 심혈관 중재시술 및 말초혈관 기기 시장의 성장이 제한되고 있습니다. 약물 용출 스텐트, 생체흡수성 혈관 스커폴드, 첨단 카테터와 같은 첨단 기술을 포함한 이러한 의료기기는 광범위한 연구 개발 및 규제 당국의 승인 절차가 필요하기 때문에 비용이 많이 드는 경우가 많습니다. 이 때문에 특히 의료 예산이 제한적이고 환자 본인 부담금이 엄청나게 높은 개발도상국에서는 이러한 의료기기에 대한 접근성이 떨어질 수 있습니다. 그 결과, 비용이 중요한 시장에서는 이러한 첨단 기기의 도입이 늦어질 수 있습니다.
높은 비용은 의료 서비스 제공자에게도 영향을 미치며, 의료 서비스 제공자는 첨단 기술 사용의 이점과 의료기관의 재정적 제약 사이의 균형을 맞춰야 합니다. 특히 공공 의료 시스템이나 보험 환급률이 낮은 지역에서는 병원과 클리닉이 예산 제약에 직면하여 고가의 새로운 장비에 투자할 수 있는 능력이 제한될 수 있습니다. 그 결과, 지리적 위치와 사회경제적 지위에 따라 환자가 받을 수 있는 의료서비스의 질에 차이가 발생하여 전체 시장의 성장을 저해할 수 있습니다.
또한, 첨단 의료기기의 높은 비용은 업계의 기술 혁신을 저해할 수 있습니다. 기업들은 비용 문제로 인해 제품 시장이 제한될 것이라고 생각한다면 신기술 개발에 투자하는 것을 주저할 수 있습니다. 그 결과, 획기적인 혁신보다는 기존 장비의 점진적인 개선에 초점을 맞추게 될 수 있습니다. 장기적으로 첨단 기기의 고비용은 가장 효과적이고 혁신적인 치료법의 보급을 가로막는 장벽이 될 수 있으며, 심혈관 중재시술 및 말초혈관 기기 시장의 성장 잠재력을 제한할 수 있습니다.
The rising global prevalence of cardiovascular diseases is driving up demand for minimally invasive procedures. The aging population, particularly in developed countries, is contributing to a higher incidence of heart and vascular diseases, necessitating advanced medical interventions evolving the market growth surpassing USD 24.08 Billion in 2024 and reachUSD 43.64 Billion by 2031.
Furthermore, ongoing technological advancements, such as the development of drug-eluting stents, bioresorbable vascular scaffolds, and novel catheter-based technologies, improve the efficacy and safety of these procedures. Increasing healthcare spending and growing awareness of the benefits of early detection and treatment of cardiovascular diseases help to drive market growth is expected to grow at aCAGR of about 8.51% from 2024 to 2031.
Interventional Cardiology and Peripheral Vascular Devices Market: Definition/ Overview
Interventional cardiology and peripheral vascular devices are specialized medical instruments and implants used to diagnose and treat conditions affecting the heart's blood vessels and peripheral arteries. Stents, catheters, balloons, and guidewires are among the devices used in minimally invasive procedures to treat coronary artery disease, peripheral artery disease, and other vascular disorders. The use of these devices is critical for restoring blood flow, lowering the risk of heart attack, and improving patient outcomes without the need for open surgery. The future of this market looks promising, thanks to technological advancements, an aging global population, and an increasing prevalence of cardiovascular diseases. Continued innovation, such as the development of bioresorbable stents and drug-eluting technologies, while expanding healthcare infrastructure in emerging markets are expected to drive the growth and adoption of these devices globally.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The growing demand for minimally invasive procedures is expected to propel the interventional cardiology and peripheral vascular devices market. In comparison to traditional open surgeries, minimally invasive techniques, such as the use of stents, balloons, and catheters, provide numerous advantages, including shorter recovery times, shorter hospital stays, and lower complication rates. As cardiovascular diseases remain a leading cause of death worldwide, the healthcare industry is increasingly relying on advanced, less invasive procedures to improve patient outcomes. These techniques are particularly popular among the elderly in developed countries, where chronic heart disease is common.
In June 2024, Medtronic received FDA approval for a new minimally invasive balloon catheter used to treat peripheral artery disease. This device enables precise treatment with minimal impact on surrounding tissue, highlighting the growing trend of non-invasive solutions in vascular care. In May 2024, Boston Scientific also introduced its latest drug-eluting stent, which is intended to reduce restenosis in coronary arteries while providing a safer and more effective alternative to open-heart surgery.
In March 2024, the European Medicines Agency (EMA) announced new regulatory initiatives to speed up the approval process for minimally invasive cardiovascular devices, recognizing the critical need for quicker access to life-saving technologies. These policies are intended to encourage more companies to innovate in the field of interventional cardiology. Overall, as healthcare systems around the world prioritize patient safety and cost-effectiveness, the demand for minimally invasive procedures is expected to fuel growth in the interventional cardiology and peripheral vascular devices market.
The high cost of advanced medical devices limits the growth of the interventional cardiology and peripheral vascular devices market. These devices, which include cutting-edge technologies such as drug-eluting stents, bioresorbable vascular scaffolds, and advanced catheters, are often expensive due to the extensive research, development, and regulatory approval processes required. This can make these devices less accessible, especially in developing countries where healthcare budgets are limited and patients' out-of-pocket costs are prohibitively high. As a result, adoption of these advanced devices may be slower in markets where cost is an important consideration.
The high cost also affects healthcare providers, who must weigh the benefits of using cutting-edge technologies against their institutions' financial constraints. Hospitals and clinics may face budgetary constraints that limit their ability to invest in costly new devices, particularly in public healthcare systems or in areas with lower insurance reimbursement rates. This can result in disparities in the quality of care available to patients based on their geographical location or socioeconomic status, potentially impeding overall market growth.
Furthermore, the high cost of advanced medical devices can stifle innovation in the industry. Companies may be hesitant to invest in the development of new technologies if they believe the market for these products is constrained by cost concerns. This could result in an emphasis on incremental improvements to existing devices rather than ground-breaking innovations. In the long run, the high cost of advanced devices may act as a barrier to widespread adoption of the most effective and innovative treatments, limiting the growth potential of the interventional cardiology and peripheral vascular devices market.
The increasing demand for drug-eluting stents (DES) is expected to drive significant growth in the interventional cardiology and peripheral vascular devices market. DES are becoming dominant due to their effectiveness in preventing restenosis, which is the re-narrowing of arteries following stent placement. These stents are coated with medication that is slowly released to reduce inflammation and the likelihood of artery reblockage, making them a better option than bare-metal stents. The benefits of DES, such as improved patient outcomes and fewer repeat procedures, are consistent with the growing global emphasis on effective and long-lasting cardiovascular treatments.
In June 2024, the European Medicines Agency (EMA) issued new guidelines to expedite the approval process for advanced cardiovascular devices, including DES. This move is intended to improve patients' access to innovative treatments throughout Europe. In May 2024 In the United States, the Food and Drug Administration (FDA) announced an initiative to increase funding for clinical trials examining the efficacy of DES in diverse populations, demonstrating a commitment to advancing the development and accessibility of these critical devices. These regulatory actions highlight the importance of DES in the cardiovascular market and support its continued expansion.
Chronic Total Occlusion (CTO) Devices are the fastest-growing segment of the market. The increasing prevalence of complex coronary artery disease, as well as technological advancements that improve the success rates of CTO procedures, are driving this growth. CTO devices are intended to treat long-term blockages in coronary arteries that have proven resistant to conventional treatments. The development of more effective and less invasive CTO devices is accelerating their adoption, reflecting a larger trend toward better solutions for difficult vascular conditions.
Rising incidences of coronary artery disease (CAD) are expected to initiate its dominance in the interventional cardiology and peripheral vascular devices market. CAD is one of the most common cardiovascular diseases in the world, owing primarily to rising risk factors such as aging populations, unhealthy lifestyles, and high obesity and diabetes rates. As CAD remains a leading cause of morbidity and mortality, there is a steady and growing demand for advanced medical devices designed to treat it. These devices, which include drug-eluting stents, coronary balloons, and advanced catheter systems, are critical for managing and alleviating the effects of CAD. The consistently high demand for these technologies demonstrates their market dominance.
In June 2024, the US Centers for Disease Control and Prevention (CDC) announced a new initiative aimed at lowering the incidence of cardiovascular disease by improving access to innovative interventional technologies. This initiative includes funding for hospitals to acquire advanced CAD treatment devices as well as enhanced healthcare provider training. Furthermore, in May 2024, the European Society of Cardiology (ESC) updated its guidelines to emphasize the use of cutting-edge interventional devices in CAD management, reflecting a growing recognition of the importance of these technologies in improving patient outcomes. These developments highlight the importance of CAD in driving market trends, as well as the ongoing focus on improving treatment options for this common condition.
Peripheral Artery Disease (PAD) is the most rapidly growing application segment. PAD's rapid growth is attributed to an aging population, rising diabetes rates, and increased awareness of the condition. PAD, which affects blood flow to the limbs, is becoming more common as lifestyle risk factors increase. Advances in treatment technologies, such as new-generation balloon catheters and atherectomy devices designed specifically for PAD, are driving market growth in this area. The emphasis on improving patient outcomes and expanding treatment options for PAD is fueling this segment's rapid growth.
Country/Region-wise
The advanced healthcare infrastructure in North America is a major driver of the interventional cardiology and peripheral vascular devices market. This region, with its well-established healthcare systems, cutting-edge medical facilities, and high healthcare expenditure, is an ideal environment for the adoption of advanced medical technologies. The presence of leading healthcare institutions and research centers promotes innovation and early adoption of new cardiovascular devices, which are essential for treating heart disease and peripheral vascular conditions. As cardiovascular diseases continue to be the leading cause of death in North America, the demand for these devices grows, driven by the need for effective and minimally invasive therapies.
The United States government has also played an important role in this development. In April 2024, the Centers for Medicare and Medicaid Services (CMS) implemented new reimbursement policies for advanced cardiovascular procedures, making these life-saving interventions more accessible to a larger patient population. This policy shift is expected to increase the adoption of interventional cardiology and peripheral vascular devices in North America, bolstering the region's global market leadership. North America's strong healthcare system, government support, and continuous innovation position it as a market leader.
The rising prevalence of cardiovascular diseases in Asia-Pacific is expected to drive rapid growth of this region in the interventional cardiology and peripheral vascular devices market. The prevalence of cardiovascular diseases in Asia-Pacific is rapidly increasing, owing to factors such as aging populations, unhealthy diets, sedentary lifestyles, and rising hypertension and diabetes rates. This increase in cardiovascular conditions is driving up demand for advanced medical devices that can effectively treat and manage these diseases, particularly through minimally invasive procedures. As a result, Asia-Pacific's interventional cardiology and peripheral vascular device markets are expected to grow significantly.
In June 2024, Medtronic announced that it had expanded its operations in India and China, two of Asia-Pacific's largest markets, to increase the availability of its most recent stents and balloon catheters. This move aims to meet the growing demand for cardiovascular treatments in these countries, where the prevalence of heart disease is rapidly increasing. Similarly, in July 2024, Boston Scientific launched a new series of drug-eluting stents in the Asia-Pacific market, specifically designed to meet the region's unique patient needs. These developments emphasize the importance of the Asia-Pacific market for major medical device manufacturers, as well as the region's growing role in the global healthcare landscape.
Asia-Pacific countries are taking proactive measures to address the rising cardiovascular disease burden. For instance, in May 2024, the Chinese government announced a new initiative to improve heart disease prevention and treatment using advanced medical technologies. This initiative includes financial incentives for hospitals to purchase cutting-edge interventional cardiology devices, as well as training programs for healthcare professionals to improve their skills in using these devices. Similarly, in April 2024, the Indian government announced that it would expand its National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), with a focus on increasing access to life-saving cardiovascular interventions. These government efforts are expected to increase the adoption of interventional cardiology and peripheral vascular devices in Asia-Pacific, driving significant market growth.
The competitive landscape of the interventional cardiology and peripheral vascular devices market is characterized by a mix of emerging players, regional manufacturers, and specialized companies focusing on niche segments. These competitors are leveraging innovative technologies and strategic partnerships to gain market share, particularly in areas like drug-eluting stents, atherectomy devices, and bioresorbable vascular scaffolds. Companies are also increasingly focusing on developing cost-effective solutions to cater to price-sensitive markets, particularly in emerging economies. Additionally, the market sees continuous product launches and FDA approvals, with smaller firms often introducing novel devices that address specific clinical needs, thus intensifying competition.
Some of the prominent players operating in the interventional cardiology and peripheral vascular devices market include:
Abbott Laboratories
Braun Melsungen AG
Biotronik SE & Co. KG
Boston Scientific Corporation
R. Bard (BD)
Cardinal Health, Inc.
Cook Medical, Koninklijke Philips N.V.
Medtronic plc
Teleflex, Inc.
Terumo Group
L. Gore & Associates, Inc.
In May 2024, Abbott introduced a new bioresorbable stent in Europe, marking a significant step forward in interventional cardiology. The stent is intended to dissolve gradually, minimizing the long-term complications associated with traditional metal stents.
In April 2024, Terumo introduced a new peripheral guidewire in Japan with the goal of improving intervention precision in complex vascular cases. This product launch is part of Terumo's strategy to broaden its offerings in the peripheral vascular device market.
In January 2024, BD received CE mark approval for its most recent vascular access device, which includes advanced antimicrobial technology to reduce infection risks during interventional procedures. This development demonstrates BD's commitment to innovation in the peripheral vascular space.
In February 2024, Cardinal Health introduced a new line of vascular closure devices in the United States, designed to reduce bleeding complications following interventional procedures. This product line is intended for hospitals seeking cost-effective and efficient closure solutions.
In March 2022, Philips announced the acquisition of a leading vascular imaging software firm, expanding its image-guided therapy portfolio. This acquisition is expected to help Philips improve its capabilities in both interventional cardiology and peripheral vascular interventions.